NIH Tetramer Core Facility
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), has issued a Solicitation (75N93026R00006) for the management and operation of the NIH Tetramer Core Facility (TCF). This facility is crucial for producing and distributing specialized antigenic reagents for T-cell research. This is a Cost-Reimbursement, Level of Effort contract. Proposals are due by June 22, 2026.
Purpose & Scope
This opportunity seeks a contractor to manage and operate the NIH Tetramer Core Facility. The TCF's primary function is to produce and distribute Research Resource Identifier (RRID)-traceable, quality-controlled, custom synthesized and premade antigenic peptide/MHC monomeric or tetrameric reagents. These reagents are used to detect, enumerate, or isolate antigen-specific T cells. The facility will also be responsible for operating and maintaining an integrated web-based system for the submission, tracking, review, distribution, and reporting of tetramer reagent requests.
Key Requirements
- Operate a centralized tetramer reagent facility.
- Produce and distribute custom synthesized and premade antigenic peptide/MHC monomeric or tetrameric reagents.
- Operate and maintain a secure, multi-functional web-based system for order submission, review, technical support, and workflow management.
- Ensure quality control and RRID traceability for all reagents.
- Support ongoing process optimization to improve reproducibility, scalability, and performance.
- Deliverables include: MHC Expression Constructs, Cell Lines, and Reagent Stocks; SOPs and Protocols; Laboratory Equipment Inventory; and Validation and Performance Documentation.
Contract Details
- Contract Type: Cost-Reimbursement, Level of Effort.
- Period of Performance: A Base Period from March 21, 2027, to March 20, 2028, followed by six one-year option periods, for a potential total of seven years.
- Estimated Level of Effort: 9 Full Time Equivalents (FTEs) per year for the Base Period and each Option Period.
- Set-Aside: This requirement is NOT set-aside for small business.
- Eligibility: Offerors must be registered in the System for Award Management (SAM).
Submission & Evaluation
- Proposals Due: Electronically via the eCPS website by 3:30 pm Eastern Time on June 22, 2026.
- Questions Due: May 6, 2026.
- Offer Validity: Offers must remain valid for 120 days.
- Evaluation Factors: Technical, Cost, and Past Performance.
Important Notes
- Attachment 1: Provides detailed instructions on proposal packaging and delivery.
- Attachment 4: Contains the Statement of Work.
- Attachment 5: Provides additional technical proposal instructions.
- Attachment 6: Provides additional business proposal instructions and uniform cost assumptions.
- Primary Contact: Zachary Fetters, zachary.fetters@nih.gov.